Environmental Impact Acquisition Corp.
Environmental Impact Acquisition — GreenLight Biosciences — Investor Presentation (August 2022)
39 slides from Environmental Impact Acquisition's investor presentation, Aug 10, 2022
Slide 1: One tool for One Health: Healthy people and planet through RNA innovation
One tool for One Health: Healthy people and planet through RNA innovation August 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains and our officers, directors and employees may make “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to GreenLight’s future operations, scienti
Slide 3: GreenLight at a glance
GreenLight at a glance Platform Agriculture Human Health Manufacturing technology Diversified RNA-based Preparing for Covid-19 that enables the cost of pipeline with 7 agricultural vaccine Phase 1 clinical RNA active ingredient for product launches planned trial in Africa agriculture at a commercial
Slide 4: Mission
Mission To solve some of the world’s largest and most difficult problems. • Food Security • Global Health Strategy • Climate Change We aim to address these problems, profitably, sustainably, and equitably by delivering on the full potential of RNA. • Control pests using double-stranded RNA • Replace
Slide 5: Our largest challenges are inextricably linked
Our largest challenges are inextricably linked GreenLight offers global, targeted, environmentally-sound solutions on Threats to food security Pandemics and global health Population growth and climate change © 2022 GreenLight Biosciences. All rights reserved. GreenLight non-confidential 5
Slide 6: Food security and climate change
Food security and climate change We need new modes of action to efficiently control pests while respecting the environment The problem Existing challenges The dsRNA advantage 1.2 contributing to Resistance • New mode of action that 2.2 Many traditional pesticides are losing seeks to increase food ef
Slide 7: Global health and climate change
Global health and climate change We need better tools to improve global health outcomes as we deal with resource insecurity in the face of climate change The problem Existing challenges The mRNA advantage 3x Pandemics are Longer lead times for preclinical • Rapid lead identification and happening it
Slide 8: Paradigm-shifting companies own their manufacturing IP
Paradigm-shifting companies own their manufacturing IP Success, historically, builds on invention, control, and acceleration of both manufacturing and product development Protein/Peptide DNA RNA dsRNA and Humanization of AAV delivery vectors & antibodies proprietary payloads mRNA proprietary Interch
Slide 9: Next RNA solutions supported by three decades of technology development
Next RNA solutions supported by three decades of technology development Advancements in RNA discovery point to key role in the future of human health and food production Applied RNA shown to affect insects dsRNA demonstrated effective Acquired for RNA in nematodes expertise and platform • GreenLight
Slide 10: Pipeline spanning plant, animal, and human health
Pipeline spanning plant, animal, and human health Projected product launches and multiple clinical milestones through 2026 Planned commercial Discovery Greenhouse Confirmatory Development Plant Health Program POC field trials launch * & lab studies trials trials & Regulatory Colorado Potato Beetle 2
Slide 11: Platform to support RNA design, development, and manufacturing
Platform to support RNA design, development, and manufacturing Proprietary plant health process creates advantages of skill and experience; human health uses separate manufacturing process Regulatory Approval dsRNA Regulatory trials Commercialization design optimization via greenhouse testing Agricu
Slide 12: GreenLight's platform adaptability and scalability validated at Samsung
GreenLight’s platform adaptability and scalability validated at Samsung Technology transfer and scale-up from lab bench to commercial facility were completed in 7 months • Commercial-scale Engineering Run 1 (ER1) successfully completed at • Our mRNA synthesis reaction had Samsung Biologics a titer o
Slide 13: GreenLight speed
GreenLight speed Operational expertise produced clinical material 18 months after initiation of work • 2Q2020: GLB leverages knowledge of agricultural dsRNA production; begins SAHPRA CTA filed with SAHPRA development of an mRNA Clinical Trial Committee consultation process for human use South Africa
Slide 14: Exceptional team with diverse public company expertise
Exceptional team with diverse public company expertise Our management team has a proven track record of success 15 Companies founded 8 Companies taken public Andrey J. Zarur, Ph.D. Susan Keefe, MBA Carole Cobb, MBA Amin Khan, Ph.D. Mark Singleton, Ph.D. CEO CFO COO Chief Scientific Officer, CCO & GM
Slide 15: Plant and animal health
Plant and animal health © 2022 GreenLight Biosciences. All rights reserved. GreenLight non-confidential 15
Slide 16: Farmers are losing crop-protection tools faster than they are being replaced
Farmers are losing crop-protection tools faster than they are being replaced EU re-registration process led to removal of the majority of existing actives; innovation has declined by 70% since the 1990s Tightening EU regulation (1991) resulted in 59% of crop- Number of new active ingredients introdu
Slide 17: Comparing our innovation to agricultural incumbents
Comparing our innovation to agricultural incumbents GreenLight’s design and development platform has enabled the creation of actives against a range of diverse crop targets 7 new active launches expected by 2026 6 actives by 20262 4 actives to launch by 20244 R&D Budgets $90M1 $1.4B3 $2B4 Sources: 1
Slide 18: RNA performs well compared to agricultural alternatives
RNA performs well compared to agricultural alternatives RNA solutions can be faster and cheaper to develop and deploy, easier to use, with greater consumer acceptability1 Years required to develop and commercialize Development cost RNA - GreenLight 5–81 $25m–$30m2 Traditional Traditional chemical pe
Slide 19: GreenLight is targeting some of food security's greatest challenges
GreenLight is targeting some of food security’s greatest challenges Our global product portfolio can address key food and agriculture industry concerns By 2050 By 2026 34% Botrytis (2025) Most fruit and vegetables Pollinator (~2024) Beehives Fusarium (2026) Wheat 7 increase in population Product lau
Slide 20: Case study: Protect potatoes
Case study: GreenLight is working to help farmers Protect potatoes RNA solution using foliar application; expected EPA approval this year; sales taking place ahead of the following growing season The problem: Colorado potato beetle causes hundreds of millions1 of damage a year and develops rapid res
Slide 21: Case study: Protect honeybees
Case study: GreenLight is working to help beekeepers Protect honeybees Proprietary solution testing in field trials; EPA submission planned this year The problem: Honeybee colonies in the United States alone contribute to pollinating more than 100 crops annually worth an estimated $18 billion1. But
Slide 22: Case study: Reduce crop loss caused by fungal pathogens
Case study: GreenLight is working to help farmers Reduce crop loss caused by fungal pathogens The problem: Fungal pathogens account for 30% of crop losses globally1–enough to feed 600 million people2. Botrytis cinerea The solution: • Causes disease in more than Current strategies involve frequent sp
Slide 23: Case study: Manage plant diseases caused by Fusarium
Case study: GreenLight is working to help farmers Manage plant diseases caused by Fusarium The problem: Fusarium cause crop loss and food waste globally, damaging grain and secreting mycotoxins harmful to humans and animals, resulting in losses of $5.6 billion1. In severe disease years, Fusarium hea
Slide 24: Rapid discovery helps address emerging climate-driven farmer pain points
Rapid discovery helps address emerging climate-driven farmer pain points Pipeline stretches from protecting honeybees to fresh produce and large-scale crops, a $10bn addressable market Phase 1a Phase 1b Phase 2 Phases 3 & 4 TAM Program Discovery & lab Regulatory Launch year * Greenhouse trials Confi
Slide 25: Human health
Human health © 2022 GreenLight Biosciences. All rights reserved. GreenLight non-confidential 25
Slide 26: GreenLight is targeting global human health challenges
GreenLight is targeting global human health challenges mRNA design flexibility coupled with our production capability can enable rapid development of vaccines and therapies 1 3 $36B pre-Covid vaccine Gene therapy Vaccine market + gene Gene program programs therapy market (*) Therapy (SCD) GreenLight
Slide 27: Case study: Covid vaccines for the rest of the world
Case study: Covid vaccines for the rest of the world The world needs more timely and accessible vaccines and therapeutics We believe our designs allow GreenLight’s Covid-19 vaccine candidate has strong preclinical performance for a production capacity of Comparable preclinical performance to other m
Slide 28: Case study: Shingles vaccine
Case study: Shingles vaccine, a global addressable market to reach $6.35B by 20281 GreenLight is designing a messenger RNA vaccine for shingles for Serum Institute of India The problem: The solution: 95% The world’s largest vaccine manufacturer, Serum Institute of India, chose GreenLight as its part
Slide 29: Case study: Genetic disorders
Case study: Genetic disorders GreenLight is building the tools to enable mRNA-mediated gene therapy The problem: LMICs are excluded from gene-therapy innovation development The solution: GreenLight gene-therapy Of 179 recruiting or near-recruiting clinical trials for gene therapies, only: architectu
Slide 30: Case study: Gene therapy for sickle cell disease
Case study: Gene therapy for sickle cell disease GreenLight is building tools to enable mRNA-mediated gene therapy The problem: The solution: Two classes of RNA molecules with distinct purposes Potential mechanism for our gene therapy architecture Sickle cell disease has no GreenLight gene-therapy c
Slide 31: An expanding Human Health pipeline
An expanding Human Health pipeline Our design and manufacturing capabilities enable development of vaccines and therapies Early Clinical Development Application Program Collaborator Pre-clinical Toxicity pre-clinical Phase 1 | Phase 2 | Phase 3 SARS-CoV-2 Vaccine (Covid-19) Seasonal Academic Vaccine
Slide 32: World-leading partnerships
World-leading partnerships We work together from the beginning of the R&D process to serve the medical needs of LMICs and address local needs • Serum Institute of India has engaged us to design three messenger RNA products, including a vaccine Funder for shingles, with an option for two additional v
Slide 33: Greenlight Biosciences: healthy people and planet through RNA innovation
Greenlight Biosciences: healthy people and planet through RNA innovation Raising to provide capital to execute on upcoming value-creation milestones Plant Health Human Health • Calantha™ registration with EPA (H2 2022) • Covid-19 Phase 1 clinical-trial data (2023) • Commercial launch of Calantha™, f
Slide 34: Promoting environmental and global health through RNA innovation
Promoting environmental and global health through RNA innovation We are committed to ESG responsibilities and to measuring our impact profitably, sustainably, and equitably Platform Agriculture Human Health Manufacturing technology that enables Diversified RNA-based pipeline with 7 Preparing for Cov
Slide 35: Thank you
Thank you 20220614
Slide 36: Appendix
Appendix 20220614
Slide 37: Risk Factors
Risk Factors: Please see GreenLight's SEC filings at the URL on page 3 of this presentation for a complete list of risk factors. In addition, please see the risk factors below. We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achiev
Slide 38: GreenLight at work
GreenLight at work ROCHESTER, NY WOBURN, MA SEVILLE, SPAIN Pilot plant for our agriculture Human health discovery, Field research station to accelerate products. Will also support initial research, clinical development transition of research and discovery commercialization of earliest MAINE compound
Slide 39: End
End 20220614
GreenLight Biosciences — Investor Presentation (August 2022) on 6ix